MSWA
TEVA icon

Marshall & Sterling Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Marshall & Sterling Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,000
Closed -$44.1K – 661
2024
Q4 		$44.1K Buy
+2,000
New +$36.4K 0.03% 137

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Marshall & Sterling Wealth Advisors's TEVA Position: Q1 2025 in Review

Marshall & Sterling Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 2,000 shares — an estimated $44.1K sold.

Marshall & Sterling Wealth Advisors first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $44.1K in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Marshall & Sterling Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Marshall & Sterling Wealth Advisors sold 2,000 Teva Pharmaceuticals shares in Q1 2025, an estimated $44.1K.
  • Marshall & Sterling Wealth Advisors first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Marshall & Sterling Wealth Advisors's Teva Pharmaceuticals position peaked at $44.1K in Q4 2024.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Marshall & Sterling Wealth Advisors's 13F filing for Q1 2025, filed 15 May 2025.